US Edition
As M&A slows, Boston’s biotech sector stands out - Capital Analytics Associates
Summary by Capital Analytics Associates
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
As M&A slows, Boston’s biotech sector stands out - Capital Analytics Associates
Writer: Mariana Hernandez July 2025 — As 2025 reaches the midpoint, Boston’s business environment reflects a national slowdown in merger and acquisition activity. But the region’s life sciences sector remains active, with billion-dollar deals and long-term investment opportunities. According to a recent report, contrary to expectations heading into the year, M&A activity has slowed in 2025 across the United States amid greater uncertainty tied t…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
